CCR4 CAR T cells for T-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new immunotherapy that targets a protein called CCR4 on certain T-cell lymphomas. The treatment uses your own immune cells, modified to find and attack cancer cells, and may help when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of T-cell lymphoma (like PTCL or CTCL) that has come back or not responded to prior treatments.
- At least 10% of your cancer cells must show the CCR4 protein on a biopsy.
- You must have tried at least two prior treatments (or one if you have ALCL, or all standard options if you have mycosis fungoides).
- You are 18 or older and have good overall health (able to do daily activities, with normal organ function).
- You must not have active infections, untreated hepatitis B or C, HIV, or certain heart, lung, or brain conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a lab-made immune therapy (CAR T cells) for lymphoma that has come back or did not respond to treatment, specifically CD30-positive T-cell lymphoma. The goal is to shrink the cancer and help keep it under control after previous therapies, including people who have relapsed after stem cell transplant.
This trial tests a new immune therapy that uses your own cells (CAR T-cells) to find and attack cancer cells with the CD19 protein. It is for people with certain types of leukemia or lymphoma that have not responded to other treatments.
This early-phase (Phase 1) study tests a lab-made immune cell treatment (CD4 CAR T) for people with CD4+ leukemia or lymphoma that has come back or did not respond to standard treatment. The goal is to check safety and see how well the treatment works.
This trial tests a type of immune treatment (CAR-T cells) for blood cancers that have come back or did not respond after standard treatments. It is for tumors that have CD19 on their cells, aiming to reduce the cancer and improve remission chances.
This trial tests a new CAR-T cell therapy (called ARI-0001) for people with certain blood cancers that have not responded to standard treatments. The treatment uses your own immune cells to fight the cancer.
This trial tests a new treatment using your own immune cells, engineered to find and attack cancer cells that have a protein called CD5. It is for people with a type of T-cell lymphoma that has come back or not responded to other treatments.
Hear when a new Peripheral T Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.